In this video, I break down Pfizer stock and answer one of the biggest questions investors are asking right now: is this 6% dividend yield a rare opportunity or a value trap? I will walk through Pfizer’s latest earnings report, 2026 guidance, valuation metrics, dividend safety, and the potential impact of drug pricing policies like Most-Favored-Nation and TrumpRx. If you’re looking for dividend stocks, defensive plays, or undervalued blue chip stocks in 2026, this deep dive into Pfizer could change how you see this pharma giant. Here's what you'll learn Pfizer’s full-year 2025 earnings and what the numbers really reveal Whether the 6.3% dividend yield is sustainable The real impact of drug pricing policy risks on margins Why Pfizer trades at just 9 times earnings Analyst price targets and the potential 30% upside My honest take on whether Pfizer belongs in a long-term portfolio Pfizer may not be a flashy growth stock, but with stable margins, billions in cash flow, and a dividend history going back to 1980, it could quietly outperform expectations. The big question is whether the market is underestimating its resilience or correctly pricing in long-term risks. Skip ahead: 0:00 - Intro 1:45 - Pfizer's overview 3:01 - PFE's price 3:35 - Recent development 6:23 - Valuation 7:27 - Verdict #Pfizer #PfizerStock #PFE #DividendStocks #HighYieldStocks #ValueInvesting #PharmaStocks #BlueChipStocks #PassiveIncome #StockMarket #Investing #LongTermInvesting #DividendIncome #DefensiveStocks #HealthcareStocks Grab Your 10 Stock Picks From Stock Advisor: https://fool.com/ricko Discord: https://rickorford.com/join Website: https://rickorford.com Try Barchart's Free Stock Screener: https://rickorford.com/barchart-stocks Don’t forget to like, subscribe, and turn on notifications for more exclusive content! DISCLAIMER: Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 19, 2026. A portion of this video is sponsored by The Motley Fool. Visit https://fool.com/ricko to get access to my special offer. The Motley Fool Stock Advisor returns are 981% as of 12/10/2025 and measured against the S&P 500 returns of 194% as of 12/10/2025. Dividend Aristocrats® is a registered trademark of Standard & Poor's Financial Services LLC. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video. This video is for educational purposes only and not financial advice. Always do your own research and consult with a financial advisor before making any investment decisions. All information and data on this YouTube Channel is solely for entertainment purposes. I'm not a financial advisor, nor licensed in any way to provide any financial advice. The information herein is based solely on my personal opinion and experience. All investments hold inherent risk, and the information provided on this YouTube Channel should not be interpreted as any kind of guidance, recommendation, offer, advice, or suggestion. Any ideas and strategies discussed on this channel should not be implemented without first considering your financial and personal circumstances or without consulting a financial professional.